X

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Low Incidence of Adverse Reactions in Clinical Trials

Zero inhibitors observed in clinical trials of previously treated patients

Development of inhibitors to Factor VIII can occur following administration of Factor VIII products.

  • If expected Factor VIII levels are not attained or bleeding is not controlled with appropriate dose, perform a Bethesda inhibitor assay to measure Factor VIII inhibitor concentration

14 of 258 patients reported an adverse event

The most common adverse reactions in clinical trials (>0.5%) were dizziness and hypersensitivity.

Adverse reactions

0.4%

Paresthesia

Rash

Erythema

Pruritus

Pyrexia

Injection-site pain

Chills

Feeling hot

0.8%

Dizziness

1.6%

Hypersensitivity

One patient withdrew due to an adverse reaction (hypersensitivity).

Study design

Data from three AFSTYLA studies: Safety of AFSTYLA was assessed in patients enrolled in the phase I/III, open-label, multicenter, crossover study, the phase III open-label study, and the ongoing phase III, open-label, multicenter extension study. Adverse reactions were reported for 14 of 258 (5.4%) patients in all studies. In the clinical studies, there have been a total of 28,418 exposure days, with at least 28,492 injections of AFSTYLA administered.

You are now leaving the current website.

Do you want to continue?

No Yes